All In Biotech

Drug Trial Radar · NCT00969410

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670)

Last checked: Nov 20, 2026Latest source record: Apr 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Aug 2009

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases. To evaluate safety and tolerability of AV-299 administered IV in subjects with advanced solid tumors who have liver metastases.

Conditions

  • Malignant Solid Tumour
  • Liver Metastases

Interventions

  • AV-299Biological

    AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of AV-299 (formerly SCH 900105) on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastasesTime frame: Screening Cycle 1: Day 1, Day 3-4: Cycle 2: Day 1 Cycle 3: Day 8-14
  2. To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastasesTime frame: DLTs assessed during first 4 weeks of treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site 1

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.